Phase I trial of single doses of IMO 3100 in healthy volunteers.

Trial Profile

Phase I trial of single doses of IMO 3100 in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2011

At a glance

  • Drugs IMO 3100 (Primary)
  • Indications Hyperlipidaemia; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Apr 2011 Results from this trial have been presented in an Idera Pharmaceuticals media release.
    • 15 Feb 2011 Status changed from active, no longer recruiting to completed.
    • 08 Jun 2010 Preliminary results have been announced by Idera Pharmaceuticals in a media release. The company plans to present detailed results at a scientific meeting in the fourth quarter of 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top